Protalix BioTherapeutics (PLX) Stock Analysis & Winston Score

Protalix BioTherapeutics is a small biotech company that makes medicines for rare genetic diseases. Its main product is taliglucerase alfa (sold as Elelyso), a treatment for Gaucher disease — a condition where the body cannot break down certain fatty substances properly. The company uses a unique plant-based manufacturing system, growing its drug proteins in carrot cells instead of the more common mammalian cell systems used by larger rivals. Protalix earns money by selling Elelyso through a partnership with Pfizer, which handles commercial distribution in most markets outside of Israel and Brazil. The company also has a second approved drug, pegunigalsidase alfa (Elfabrio), for Fabry disease, developed with Chiesi Farmaceutici. Operating in a niche rare-disease space gives Protalix some pricing power, but its small size and dependence on a limited number of drugs create meaningful concentration risk. The key growth driver is expanding Elfabrio's market share in Fabry disease, where it competes against established treatments from larger companies.